

Active ingredients | Message type | Date of the last message | Type of reason |
Olanzapine | Change notification | 09.02.2025 | Production problem |
Pramipexole dihydrochloride monohydrate | Initial notification | 07.02.2025 | Other |
Amoxicillin trihydrate | Change notification | 07.02.2025 | Other |
Carboplatin | Change notification | 07.02.2025 | Other |
Doxorubicin hydrochloride | Change notification | 07.02.2025 | Other |
Aprepitant | Initial notification | 07.02.2025 | Other |
Proxymetacaine hydrochloride | Initial notification | 07.02.2025 | Production problem |
Moxifloxacin hydrochloride (Ph.Eur.) ((with information on water content (1:x))) | Initial notification | 06.02.2025 | Other |
ofloxacin | Initial notification | 06.02.2025 | Production problem |
Paliperidone palmitate | Initial notification | 06.02.2025 | Other |
Insulin aspart | Initial notification | 06.02.2025 | Production problem |
Paliperidone palmitate | Initial notification | 06.02.2025 | Other |
Carbamazepine | Change notification | 06.02.2025 | Other |
Urapidil | Change notification | 06.02.2025 | Other |
Hydromorphone hydrochloride | Change notification | 06.02.2025 | Other |
Hydrocortisone | Change notification | 06.02.2025 | Other |
Insulin glargine | Initial notification | 05.02.2025 | Other |
Salbutamol sulfate | Change notification | 05.02.2025 | Other |
Aprepitant | Initial notification | 05.02.2025 | Other |
Cyclophosphamide monohydrate | Change notification | 05.02.2025 | Other |
Tacrolimus monohydrate | Initial notification | 05.02.2025 | Other |
Betamethasone valerate (Ph.Eur.) | Initial notification | 05.02.2025 | Other |
Mometasone furoate (Ph.Eur.) | Initial notification | 05.02.2025 | Other |
Hydrocortisone | Initial notification | 05.02.2025 | Other |
Betamethasone dipropionate (Ph.Eur.); gentamicin sulphate | Initial notification | 05.02.2025 | Other |
Rotigotine | Initial notification | 04.02.2025 | Other |
Cytarabine | Initial notification | 04.02.2025 | Production problem |
Oxycodone hydrochloride | Initial notification | 04.02.2025 | Other |
Moxifloxacin hydrochloride (Ph.Eur.) ((with information on water content (1:x))) | Initial notification | 04.02.2025 | Other |
Quetiapine fumarate (Ph.Eur.) | Change notification | 04.02.2025 | Other |
Quetiapine fumarate (Ph.Eur.) | Initial notification | 03.02.2025 | Production problem |
Azithromycin dihydrate | Initial notification | 03.02.2025 | Other |
Carbamazepine | Change notification | 03.02.2025 | Production problem |
Azithromycin dihydrate | Change notification | 03.02.2025 | Other |
Medroxyprogesterone acetate | Change notification | 03.02.2025 | Other |
Galantamine hydrobromide | Change notification | 03.02.2025 | Production problem |
Quetiapine fumarate (Ph.Eur.) | Change notification | 03.02.2025 | Production problem |
Amlodipine besylate; perindopril tert-butylamine | Change notification | 03.02.2025 | Production problem |
Dexamethasone; gentamicin sulphate | Change notification | 03.02.2025 | Production problem |
Ingredients | Status | Update | Specialty |
poractant alfa | Supply tension | 07/02/2025 | Curosurf, suspension for endotracheobronchial instillation – |
disopyramide (phosphate) | Supply tension | 07/02/2025 | Rythmodan 250 mg sustained-release, coated tablet – |
etoposide | Out of stock | 07/02/2025 | Etoposide Accord 20 mg/ml, dilutable solution for infusion – |
paliperidone | Supply tension | 06/02/2025 | Xeplion, prolonged-release suspension for injection – |
acetazolamide | Supply tension | 06/02/2025 | Diamox 250 mg, scored tablet – |
levofloxacin | Supply tension | 06/02/2025 | Specialties based on Levofloxacin 500 mg scored film-coated tablet – |
icatibant (acetate) | Remise à disposition | 05/02/2025 | Icatibant Viatris 30 mg, solution for injection in pre-filled syringe – |
risperidone | Supply tension | 05/02/2025 | Risperidone 0.5 mg, 1 mg, 2 mg 3 mg and 4 mg orodispersible tablet – |
triamcinolone (acetonide of) | Available for use | 04/02/2025 | Kenacort Retard 40 mg/1 ml, suspension for injection – |
diltiazem (hydrochloride) | Supply tension | 03/02/2025 | Bi Tildiem L.P. 90 mg, sustained-release coated tablet – |
etoposide | Supply tension | 03/02/2025 | Etoposide Teva, solution for infusion – |
Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
paclitaxel | Injection, concentrated | 6 mg/mL | Resolved | Available | Manufacturing | 7/02/2025 |
colistimethate sodium | Injection, powder for | IU | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 7/02/2025 |
olanzapine | Tablet, orally disintegrating | 20 mg | Anticipated | Available | Manufacturing | 7/02/2025 |
levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 7/02/2025 |
capecitabine | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in consumer demand | 7/02/2025 |
nicorandil | Tablet | 10 mg | Anticipated | Available | Manufacturing | 7/02/2025 |
ivabradine hydrochloride | Tablet, film coated | 5.39 mg | Resolved | Available | Manufacturing | 7/02/2025 |
fentanyl citrate | Injection, solution | 157 microgram | Resolved | Available | Manufacturing | 7/02/2025 |
fluorouracil | Cream | 50 mg/g | Current | Unavailable | Manufacturing | 7/02/2025 |
clindamycin phosphate | Lotion | 10 mg/mL | Resolved | Available | Manufacturing | 7/02/2025 |
ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~6.28 microgram/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 7/02/2025 |
ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~6.28 microgram/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 7/02/2025 |
citalopram hydrobromide | Tablet, film coated | 49.96 mg | Anticipated | Available | Manufacturing | 7/02/2025 |
carvedilol | Tablet, film coated | 6.25 mg | Resolved | Available | Manufacturing | 6/02/2025 |
ramipril | Capsule, hard | 1.25 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
octreotide | Injection, solution | 100 microgram | Current | Limited Availability | Manufacturing | 6/02/2025 |
octreotide | Injection, solution | 500 microgram | Current | Unavailable | Manufacturing | 6/02/2025 |
octreotide | Injection, solution | 50 microgram | Current | Limited Availability | Manufacturing | 6/02/2025 |
topiramate | Tablet, film coated | 200 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
olanzapine | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
amisulpride | Tablet | 100 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
galantamine hydrobromide | Capsule, modified release | 10.252 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
montelukast sodium | Tablet, chewable | 4.16 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
trandolapril | Capsule, hard | .5 mg | Resolved | Available | Manufacturing | 6/02/2025 |
trandolapril | Capsule, hard | 1 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Unexpected increase in consumer demand | 6/02/2025 |
quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Unexpected increase in consumer demand | 6/02/2025 |
quetiapine fumarate | Tablet, modified release | 57.565 mg | Anticipated | Available | Unexpected increase in consumer demand | 6/02/2025 |
candesartan cilexetil | Tablet, uncoated | 4 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
esomeprazole | Capsule, enteric | 40 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
dosulepin (dothiepin) hydrochloride | Tablet, film coated | 75 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 6/02/2025 |
doxepin hydrochloride | Capsule, hard | 11.3 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 6/02/2025 |
atorvastatin calcium trihydrate | Tablet, film coated | 43.376 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Unexpected increase in consumer demand | 6/02/2025 |
levothyroxine sodium | Tablet, uncoated | 50 microgram | Current | Unavailable | Manufacturing | 6/02/2025 |
metformin hydrochloride | Tablet, film coated | 850 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 6/02/2025 |
alprostadil | Injection, powder for | 40 microgram/mL | Current | Unavailable | Manufacturing | 6/02/2025 |
nizatidine | Capsule | 150 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
betiatide | Injection, powder for | 1 mg | Current | Unavailable | Manufacturing | 5/02/2025 |
acetylcholine chloride | Solution, powder for irrigation | 10 mg/mL | Current | Limited Availability | Manufacturing | 5/02/2025 |
sumatriptan succinate | Tablet, film coated | 140 mg | Current | Unavailable | Manufacturing | 5/02/2025 |
sugammadex sodium | Injection, solution | 217.6 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 5/02/2025 |
acetylcysteine | Injection, concentrated | 2 g | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 5/02/2025 |
nicotinic acid | Tablet, uncoated | 250 mg | Resolved | Available | Manufacturing | 5/02/2025 |
fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 5/02/2025 |
deferasirox | Tablet, film coated | 90 mg | Anticipated | Available | Manufacturing | 5/02/2025 |
melatonin | Oral Liquid, solution | 1 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 5/02/2025 |
carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Current | Limited Availability | Manufacturing | 5/02/2025 |
imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 5/02/2025 |
norethisterone~ethinylestradiol | Tablet, uncoated | 1 mg~36 microgram | Current | Limited Availability | Manufacturing | 5/02/2025 |
citalopram hydrobromide | Tablet, film coated | 24.98 mg | Current | Limited Availability | Manufacturing | 5/02/2025 |
nizatidine | Capsule | 300 mg | Resolved | Available | Manufacturing | 5/02/2025 |
sodium pertechnetate(99mTc) | Injection, solution | 18.5 GBq | Current | Unavailable | Manufacturing | 4/02/2025 |
clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 4/02/2025 |
midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 4/02/2025 |
adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 4/02/2025 |
mesalazine | Tablet, enteric coated | 800 mg | Current | Limited Availability | Manufacturing | 4/02/2025 |
emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Manufacturing | 4/02/2025 |
Influenza virus haemagglutinin | Injection, suspension | 15 microgram | Current | Unavailable | Seasonal depletion of stock | 4/02/2025 |
mefenamic acid | Capsule, hard | 250 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 4/02/2025 |
nebivolol hydrochloride | Tablet | 5.45 mg | Resolved | Available | Manufacturing | 4/02/2025 |
Influenza virus haemagglutinin | Injection, suspension | 15 microgram | Current | Unavailable | Seasonal depletion of stock | 4/02/2025 |
albendazole | Tablet, chewable | 200 mg | Resolved | Available | Manufacturing | 4/02/2025 |
cisatracurium besilate | Injection, solution | 2.68 mg/mL | Current | Unavailable | Manufacturing | 4/02/2025 |
estradiol~norethisterone acetate | Drug delivery system, transdermal | .62 mg~2.7 mg | Current | Unavailable | Manufacturing | 4/02/2025 |
hydrocortisone acetate | Eye Ointment | 10 mg/g | Resolved | Available | Manufacturing | 3/02/2025 |
fentanyl | Drug delivery system, transdermal | 4.2 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2025 |
tramadol hydrochloride | Tablet, modified release | 200 mg | Resolved | Available | Manufacturing | 3/02/2025 |
silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 3/02/2025 |
silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 3/02/2025 |
heparin sodium | Injection, solution | 25000 IU/mL | Resolved | Available | Manufacturing | 3/02/2025 |
ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.583 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 10.396 mg~10 mg | Current | Limited Availability | Manufacturing | 3/02/2025 |
ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.791 mg | Current | Limited Availability | Manufacturing | 3/02/2025 |
ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Current | Limited Availability | Manufacturing | 3/02/2025 |
midazolam | Injection, solution | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 3/02/2025 |
eftrenonacog alfa | Injection, powder for | 250 IU | Resolved | Available | Unexpected increase in consumer demand | 3/02/2025 |
atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 43.4 mg~10 mg | Resolved | Available | Manufacturing | 3/02/2025 |
atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 86.8 mg~10 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2025 |
olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~6.935 mg | Resolved | Available | Manufacturing | 3/02/2025 |
nebivolol hydrochloride | Tablet | 1.363 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
clobazam | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
dasatinib propylene glycol | Tablet, film coated | 58 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
dasatinib propylene glycol | Tablet, film coated | 81.2 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
dasatinib propylene glycol | Tablet, film coated | 116 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
nitrofurantoin | Capsule, hard | 100 mg | Anticipated | Available | Manufacturing | 3/02/2025 |
clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
carboplatin | Injection, solution | 10 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2025 |